Last edition
News about "Datroway"
AstraZeneca Completes USD 2B Equity Investment in Summit Therapeutics
AstraZeneca has completed its USD 2 billion equity investment in Summit Therapeutics to advance ivonescimab-based cancer treatment combinations.
Datroway | 06/10/2026 | By News Bureau
Japan Approves Enhertu and Datroway for New First-Line Metastatic Breast Cancer Indications
Japan has approved new first-line metastatic breast cancer indications for Daiichi Sankyo’s Enhertu and Datroway, expanding treatment options for patients with HER2-positive and triple-negative breast cancer.
Datroway | 17/09/2026 | By News Bureau | 417
The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.
Datroway | 27/08/2026 | By News Bureau
EU Approves Datroway for First-Line Metastatic TNBC
The European Union (EU) has approved AstraZeneca and Daiichi Sankyo's Datroway for first-line metastatic Triple Negative Breast Cancer (TNBC), backed by positive phase 3 survival and PFS results.
Datroway | 01/08/2026 | By News Bureau | 149
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Datroway | 29/06/2026 | By News Bureau | 166
Daiichi Sankyo Unveils 5-Year Oncology Growth Strategy
Daiichi Sankyo launches a 5-year strategy targeting global oncology leadership, aiming for 2.3 trillion yen in oncology revenue by 2030 through new indications, breakthrough technologies, and expanded commercialisation capabilities.
Datroway | 12/05/2026 | By News Bureau | 304
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
Datroway | 14/01/2026 | By News Bureau | 339
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy